http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2473613-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3c73f3e090f46155ac787d57c5796c5f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0038 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P13-14 |
| filingDate | 2010-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa74c92252fe374de038001be8c1911c |
| publicationDate | 2012-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2473613-A2 |
| titleOfInvention | Cancer starvation therapy |
| abstract | The present invention is a glutamine analogue which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction. |
| priorityDate | 2009-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.